Kiyoshi Yamashita

Miyazaki, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab.

Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab.

Journal: Clinical immunology (Orlando, Fla.)
Published: July 01, 2025

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

Journal: Blood cell therapy
Published: December 23, 2024

Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.

Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.

Journal: International journal of hematology
Published: October 17, 2024

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

Journal: Blood cell therapy
Published: October 27, 2023

Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan.

Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan.

Journal: International journal of hematology
Published: October 26, 2023

The clinical impact of the ratio of C-reactive protein to albumin (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma (ATL).

The clinical impact of the ratio of C-reactive protein to albumin (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma (ATL).

Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 28, 2023

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.

Journal: Haematologica
Published: June 02, 2022

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.

Journal: Viruses
Published: February 28, 2022

Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Journal: Internal medicine (Tokyo, Japan)
Published: January 13, 2022

Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.

Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.

Journal: International journal of hematology
Published: March 19, 2021

Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

Journal: Journal of clinical medicine
Published: November 04, 2020

Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.

Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.

Journal: European journal of haematology
Published: October 15, 2020
Showing 1-12 of 43

Last Updated: 09/26/2026